Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mertiva AB

www.mertiva.se

Latest From Able Laboratories Inc.

Sun Starts Integration Of GSK's Opiates Business

Sun Pharmaceutical Industries has started the integration of its opiates business in Australia, acquired earlier this year from GlaxoSmithKline, following the completion of the deal.

Australia

Sun builds controlled substances play with GSK opiates buy

Sun Pharmaceutical Industries has acquired GlaxoSmithKline's opiates business in Australia – a move that is expected to help the Indian firm build significantly on its interests in the controlled substances space.

Neurology Hungary

Yaupon Therapeutics Inc.

With a comparatively small amount of private equity capital raised to date, specialty pharma Yaupon Therapeutics Inc. has quickly managed to establish a four-compound pipeline and to move two of its candidates-one a drug for methamphetamine addiction, the other a topical agent for cutaneous T-cell lymphoma--into the clinic.

Orthopedic Opportunities

Managed care has sent orthopedics companies searching for new ways to lower or justify the costs of bone-repair and replacement. Surgeons have lost the freedom to select favorite products and now look to the bottom line. Companies are trying to use molecular biology and materials advances to develop products that will look and act like natural bone, and so produce better, longer-lasting healing. Yet safety and liability concerns, and memories of past disappointments, are keeping financiers skeptical.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Diamyd Medical AB
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Sweden
  • Parent & Subsidiaries
  • Mertiva AB
  • Senior Management
  • Andreas Bergsten, CEO
    Anna Styrud, CFO
    Erika Hillborg, Sr. Dir., Clin. Dev.
  • Contact Info
  • Mertiva AB
    Phone: (46) 8 661 00 26
    Karlavagen 108
    Stockholm, SE-115 26
    Sweden
Advertisement
Advertisement
UsernamePublicRestriction

Register